MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jnnp-2020-323458

Медицинская библиотека · Journal of neurology, neurosurgery, and psychiatry · 2020

Prior antiplatelet therapy and haematoma expansion after primary intracerebral haemorrhage: an individual patient-level analysis of CLEAR III, MISTIE III and VISTA-ICH.

Murthy Santosh, Roh David J, Chatterjee Abhinaba, McBee Nichol, Parikh Neal S, Merkler Alexander E, Navi Babak B, Falcone Guido J, Sheth Kevin N, Awad Issam, Hanley Daniel, Kamel Hooman, Ziai Wendy C, CLEAR III, MISTIE III and VISTA-ICH Collaborators

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the relationship between prior antiplatelet therapy (APT) and outcomes after primary intracerebral haemorrhage (ICH), and assess if it varies by haematoma location.

METHODS

We pooled individual patient data from the Virtual International Stroke Trials Archive-ICH trials dataset, Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III trial and the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation Phase III trial. The exposure was APT preceding ICH diagnosis. The primary outcome was haematoma expansion at 72 hours. Secondary outcomes were admission haematoma volume, all-cause mortality, death or major disability (modified Rankin Scale (mRS) score ≥4) and shift in mRS distribution. Mixed-effects models were used to assess the relationship between APT and outcomes. Secondary analyses were stratified by ICH location and study cohort.

RESULTS

Among 1420 patients with ICH, there were 782 (55.1%) lobar and 596 (42.0%) deep haemorrhages. APT was reported in 284 (20.0%) patients. In adjusted regression models, prior APT was not associated with haematoma expansion (OR, 0.97; 95% CI 0.60 to 1.57), major disability or death (OR, 1.05; 95% CI 0.61 to 1.63), all-cause mortality (OR, 0.89; 95% CI 0.47 to 1.85), admission haematoma volume (beta, -0.17; SE, 0.09; p=0.07) and shift in mRS (p=0.43). In secondary analyses, APT was associated with admission haematoma volume in lobar ICH (beta, 0.25; SE, 0.12; p=0.03), but there was no relationship with other ICH outcomes when stratified by haematoma location or study cohort.

CONCLUSIONS

In a large heterogeneous cohort of patients with ICH, prior APT was not associated with haematoma expansion or functional outcomes after ICH, regardless of haematoma location. APT was associated with admission haematoma volumes in lobar ICH.

Для цитирования: Murthy Santosh, Roh David J, Chatterjee Abhinaba, McBee Nichol, Parikh Neal S, Merkler Alexander E, Navi Babak B, Falcone Guido J, Sheth Kevin N, Awad Issam, Hanley Daniel, Kamel Hooman, Ziai Wendy C, CLEAR III, MISTIE III and VISTA-ICH Collaborators. Prior antiplatelet therapy and haematoma expansion after primary intracerebral haemorrhage: an individual patient-level analysis of CLEAR III, MISTIE III and VISTA-ICH.. Journal of neurology, neurosurgery, and psychiatry. 2020. DOI: 10.1136/jnnp-2020-323458.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.